Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 28, 2007; 13(44): 5857-5866
Published online Nov 28, 2007. doi: 10.3748/wjg.v13.i44.5857
Published online Nov 28, 2007. doi: 10.3748/wjg.v13.i44.5857
Table 1 Anti-VEGF agents currently in clinical development
Agent | Targets | Phase of development |
Specific anti-VEGF antibodies | ||
Bevacizumab (Avastin) | VEGF-A | Phase III |
IMC-C1121b | VEGFR-2 | PhaseI-II |
VEGF Trap | VEGF, PlGF, VEGF-B | Phase I |
Agents that target VEGF receptors tyrosine kinase | ||
Vatalanib (PTK787/ZK 222584) | VEGFR1, VEGFR2, VEGFR3, PDGFR-β, c-Kit | Phase III |
Sorafenib (BAY 43-9006) | VEGFR-2, PDGFR-β, FLT3, c-Kit, Raf | Phase III |
Sunitinib (SU11248) | VEGFR2, PDGFR-β, FLT3, c-Kit | Phase III |
Semaxanib (SU5416) | VEGFR1, VEGFR2 | Stopped |
AZD2171 | VEGFR1, VEGFR2, VEGFR3, PDGFR-β, c-Kit | PhaseI-II |
CEP-7055 | VEGFR1, VEGFR2, VEGFR3 | PhaseI-II |
CHIR258 | VEGFR1, VEGFR2, FGFR1, FGFR3 | |
CP-547632 | VEGFR2 | PhaseI-II |
GW786034 | VEGFR2 | PhaseI-II |
OSI-930 | VEGFR, c-Kit | PhaseI-II |
ZK-CDK | VEGFRs, PDGFR, CDKs | PhaseI-II |
AG013736 | VEGFR, PDGFR-β, c-Kit | PhaseI-II |
AMG706 | VEGFR1, VEGFR2, PDGFR-β, c-Kit | PhaseI-II |
KRN-951 | VEGFR1, VEGFR2, VEGFR3, PDGFR-β, c-Kit | PhaseI-II |
BMS-582664 | VEGFR2, FGFR | PhaseI-II |
XL999 | FGFR, VEGFRs, PDGFR, FLT3 | PhaseI-II |
Zactima (ZD6474) | VEGFR2, EGFR, RET | PhaseI-II |
AEE788 | VEGFR1, VEGFR2, EGFR | PhaseI-II |
Antisense oligonucleotides | ||
Veglin (VEGF-AS) | VEGF, VEGF-C, VEGF-D | PhaseI |
Aptamer | ||
Aplidin (Dehydrodidemnin B) | VEGF | PhaseI |
- Citation: Prat A, Casado E, Cortés J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 2007; 13(44): 5857-5866
- URL: https://www.wjgnet.com/1007-9327/full/v13/i44/5857.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i44.5857